Mr. Armando Anido, Chief Executive Officer and President, will host the conference call.

Conference call details:
Date:                           Wednesday, October 28, 2009
Time:                           10:00 a.m. EDT
Dial-in (U.S.):                 866-804-6923
Dial-in (International):        857-350-1669
Web cast:                       http://www.auxilium.com
Passcode:                       AUXILIUM
To access an audio replay of the call:
Access number (U.S.):           888-286-8010
Access number (International):  617-801-6888
Replay Passcode #:              83089898

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX(TM) (collagenase clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's contracture, and the biologics license application is under review at the FDA for the treatment of Dupuytren's contracture. XIAFLEX is in phase IIb of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development. The Company is currently seeking a partner to further develop these product candidates. Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system.